Caribou Biosciences, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1420381089
USD
1.68
0.05 (3.07%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.87 M

Shareholding (Mar 2025)

FII

9.49%

Held by 64 FIIs

DII

57.45%

Held by 30 DIIs

Promoter

11.74%

How big is Caribou Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Caribou Biosciences, Inc. has a market capitalization of 107.89 million and reported net sales of 9.91 million with a net profit of -147.86 million over the latest four quarters.

As of Jun 18, Caribou Biosciences, Inc. has a market capitalization of 107.89 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 9.91 million, while the sum of net profit for the same period is -147.86 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 252.95 million and total assets at 320.85 million.

Read More

What does Caribou Biosciences, Inc. do?

22-Jun-2025

Caribou Biosciences, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, with recent net sales of $2 million and a net loss of $40 million. It has a market cap of $107.89 million and key metrics indicating significant financial challenges, including a negative return on equity and no dividend yield.

Overview: <BR>Caribou Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -40 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 107.89 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.95 <BR>Return on Equity: -69.02% <BR>Price to Book: 0.50<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Should I buy, sell or hold Caribou Biosciences, Inc.?

22-Jun-2025

Is Caribou Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of July 31, 2025, Caribou Biosciences, Inc. shows a mildly bullish technical trend, but mixed indicators and underperformance compared to the S&P 500 suggest caution.

As of 31 July 2025, the technical trend for Caribou Biosciences, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. However, the weekly RSI is bearish, and the monthly RSI shows no signal. The daily moving averages are mildly bullish, and the weekly KST is bullish, but the monthly KST is bearish. The weekly Bollinger Bands indicate a mildly bullish stance, while the monthly Bollinger Bands are bearish. Dow Theory shows a mildly bearish trend on the weekly timeframe with no trend on the monthly.<BR><BR>In terms of performance, Caribou has underperformed the S&P 500 over the past week and month, with returns of -6.81% and -4.81% compared to the S&P 500's 1.05% and 2.33%, respectively. However, year-to-date, Caribou is slightly behind the S&P 500 with a return of 11.95% versus 12.22%. Over the past year, Caribou has declined by 14.42%, while the S&P 500 has gained 17.14%. Overall, the current technical stance is mildly bullish, but mixed indicators suggest caution.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate -217.77% of over the last 5 years

 
2

The company has declared Negative results for the last 5 consecutive quarters

3

Risky - Negative EBITDA

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 169 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.09

stock-summary
Return on Equity

-86.55%

stock-summary
Price to Book

1.01

Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
-54 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.59%
0%
-0.59%
6 Months
31.25%
0%
31.25%
1 Year
-7.18%
0%
-7.18%
2 Years
-73.12%
0%
-73.12%
3 Years
-75.22%
0%
-75.22%
4 Years
-89.37%
0%
-89.37%
5 Years
0%
0%
0.0%

Caribou Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-8.02%
EBIT Growth (5y)
-217.77%
EBIT to Interest (avg)
-104.21
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.95
Sales to Capital Employed (avg)
0.07
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
91.24%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.54
EV to EBIT
0.55
EV to EBITDA
0.56
EV to Capital Employed
-8.39
EV to Sales
-9.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-69.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 49 Schemes (21.13%)

Foreign Institutions

Held by 64 Foreign Institutions (9.49%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 12.50% vs 14.29% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -35.25% vs -12.68% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.70",
          "val2": "2.40",
          "chgp": "12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-34.30",
          "val2": "-41.70",
          "chgp": "17.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-20.90",
          "val2": "0.30",
          "chgp": "-7,066.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-54.10",
          "val2": "-40.00",
          "chgp": "-35.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,283.80%",
          "val2": "-18,237.60%",
          "chgp": "495.38%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -71.01% vs 148.20% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -46.03% vs -2.72% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.00",
          "val2": "34.50",
          "chgp": "-71.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-162.70",
          "val2": "-112.50",
          "chgp": "-44.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.20",
          "val2": "-1.30",
          "chgp": "269.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-149.10",
          "val2": "-102.10",
          "chgp": "-46.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-16,671.60%",
          "val2": "-3,366.30%",
          "chgp": "-1,330.53%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
2.70
2.40
12.50%
Operating Profit (PBDIT) excl Other Income
-34.30
-41.70
17.75%
Interest
0.00
0.00
Exceptional Items
-20.90
0.30
-7,066.67%
Consolidate Net Profit
-54.10
-40.00
-35.25%
Operating Profit Margin (Excl OI)
-13,283.80%
-18,237.60%
495.38%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 12.50% vs 14.29% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -35.25% vs -12.68% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
10.00
34.50
-71.01%
Operating Profit (PBDIT) excl Other Income
-162.70
-112.50
-44.62%
Interest
0.00
0.00
Exceptional Items
2.20
-1.30
269.23%
Consolidate Net Profit
-149.10
-102.10
-46.03%
Operating Profit Margin (Excl OI)
-16,671.60%
-3,366.30%
-1,330.53%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -71.01% vs 148.20% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -46.03% vs -2.72% in Dec 2023

stock-summaryCompany CV
About Caribou Biosciences, Inc. stock-summary
stock-summary
Caribou Biosciences, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available